Prevalence and Correlates of Anemia in a Large Cohort of HIV-Infected Women: Women's Interagency HIV Study

Levine, Alexandra M.; Berhane, Kiros; Masri-Lavine, Lena; Sanchez, Maria Lynn; Young, Mary; Augenbraun, Michael; Cohen, Mardge H.; Anastos, Kathryn; Newman, Margaret; Gange, Stephen J.; Watts, Heather

doi:10.1097/00042560-200101010-00004

Cited by 59 publications

(63 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women's Interagency HIV Study (WIHS) reported the presence of anemia in 42.6% of HIV-infected women patients receiving AZT therapy compared with 34.3% of those not receiving AZT. 3 Furthermore, Agarwal et al 11 reported a high incidence of AZT-induced anemia (42.7%) in HIV-infected patients from eastern part of India. In contrast Semba et al 12 reported that, although the use of zidovudine was associated with an increased risk of anemia in the pre-HAART era (1993)(1994)(1995)(1996), use of zidovudine during the HAART era (1996-2000) was not significantly associated with anemia.…”

Section: Discussionmentioning

confidence: 99%

“…The first group was HIV patients with CD 4 cell counts 200-350 cell/mm 3 , and the second group was HIV patients with CD 4 cell counts ≥350 cell/mm 3 . All available demographics (age, gender, body height and body weight), clinical (history of diseases and history of treatment) and laboratory (viral load counts, CD 4 cell counts and Hb level) data of subjects before AZT-based ART were then recorded.…”

Section: Methodsmentioning

confidence: 99%

“…Other than blood loss, the pathophysiology of HIV associated anemia may involve decreased red blood cell (RBC) production, increased RBC destruction and ineffective RBC production. 1,3 Factors associated with anemia in HIV patients include HIV infection itself, HIV-related opportunities infections or as a consequence of drug used for HIV infection and associated condition. 4,5 Several drugs that commonly cause anemia in HIV patients have been reported.…”

Section: Introductionmentioning

confidence: 99%

“…[6][7][8] Another factor currently associated with anemia in HIV patients is CD 4 cell counts. It was reported that 3.2% of asymptomatic HIVseropositive patients with CD 4 cell counts greater than 700 cells/mm 3 were anemic, where as anemia was observed in 20.9% of those with CD 4 cell counts less than 249 cells/ mm 3 . 9 Furthermore, CD 4 cell counts less than 25…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Risk of zidovudine-induced anemia on human immunodeficiency virus (HIV) infection patients with different CD 4 cell counts

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk of zidovudine-induced anemia on human immunodeficiency virus (HIV) infection patients with different CD 4 cell counts

et al. 2017

View full text Add to dashboard Cite

“…8,13 Two types of anaemia may occur with AZT therapy marcrocytic megaloblastic anaemia and normochromic anaemia. 14,15 Several subacute and subchronic rodent toxicity studies have demonstrated that the primary toxicity of AZT is myelosuppression. A recent study evaluated the effects of AZT on hemostatic and hematologic parameters in Wistar rats and found out a significant decrease in RBCs, PCV and platelet count.…”

Section: Introductionmentioning

confidence: 99%

Azidothymidine induces severe hematological toxicity and hepatic injury in Charles Foster rats

Pandey¹,

Singh²

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: The present study aimed at evaluating the effects of azidothymidine (AZT) on hematologic and biochemical parameters in Charles Foster rats.Methods: Twelve adult healthy Charles Foster rats comprising of six male and six females were selected for study. Test rodents were divided into four groups containing three rodents each. Three males and three females served as control and remaining received AZT drug. Rodents were acclimatized for 10 days and drug was administered for 28 days. After the completion of drug administration, blood samples were collected and analyzed for hematologic parameters, i.e., Hemoglobin (Hb), Packed cell volume (PCV), red blood cell (RBC), Mean corpuscular hemoglobin concentration (MCHC), total leukocyte count (TLC), Mean corpuscular volume (MCV), Platelet count (Plt) using a Fully Automatic Fully Digital Hematology Cell Counter. In addition, biochemical parameters, were measured to assess the effects of AZT on rodent physiology. In-vivo histopathological studies were also performed on vital organs of rodents to understand the effects of drug at tissue level.Results: When compared with the control group, the data indicated a outstanding decrease in Hb, PCV, RBC, TLC and platelets in all test groups, whereas MCHC did not show any major reduction but MCV data suggested a slight increase. Among biochemical parameters, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP). were found to be remarkably elevated along with elevated bilirubin and reduced albumin, pointing towards a possible liver damage which was later corroborated by liver histopathological study.Conclusions: Above results indicate azidothymidine to be a myelosuppresive and hepatotoxic drug and its usage as an anti-retro viral during highly active anti-retro viral therapy (HAART) regime should be strictly monitored.

show abstract

Epoetin Alfa

Henry¹,

Bowers²,

Romano³

et al. 2004

Arch Intern Med

View full text Add to dashboard Cite

Recombinant human erythropoietin (epoetin alfa) has been used in clinical settings for more than a decade. Its indications have expanded considerably from its original use as hormone therapy in the treatment of anemia in adults with chronic kidney disease. Since the introduction of epoetin alfa, a greater understanding of anemia pathophysiology and the interactions of erythropoietin, iron, and erythropoiesis has been elucidated. Anemia is now independently associated with increased mortality and disease progression. Potential survival benefits associated with correction of anemia in various patient populations are leading to consideration of earlier, more aggressive treatment of mild to moderate anemia with epoetin alfa. Moreover, this agent's therapeutic use may extend beyond currently accepted roles. Epoetin alfa is undergoing evaluation with promising results in a variety of new clinical settings, including anemia associated with congestive heart failure, ribavirin-interferon alfa treatment of hepatitis C virus infection, and critical illness. Preclinical studies also have established erythropoietin and its recombinant equivalent to be a pleiotropic cytokine with antiapoptotic activity and neuroprotective actions in the central nervous system. The therapeutic potential of epoetin alfa appears yet to be fully realized.

show abstract

Prevalence and Correlates of Anemia in a Large Cohort of HIV-Infected Women: Women's Interagency HIV Study

Cited by 59 publications

References 22 publications

Risk of zidovudine-induced anemia on human immunodeficiency virus (HIV) infection patients with different CD 4 cell counts

Risk of zidovudine-induced anemia on human immunodeficiency virus (HIV) infection patients with different CD 4 cell counts

Azidothymidine induces severe hematological toxicity and hepatic injury in Charles Foster rats

Epoetin Alfa

Contact Info

Product

Resources

About